Pulmonary Hypertension in Left Heart Disease

Description

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

Conditions

Pulmonary Hypertension, Pulmonary Vascular Disease, Left Heart Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

Comparison of Noninvasively-Obtained Echocardiographic Doppler Parameters With Simultaneously-Measured Invasive Hemodynamics in Patients Referred for Right Heart Catheterization

Pulmonary Hypertension in Left Heart Disease

Condition
Pulmonary Hypertension
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason.
  • * Left Heart Disease, defined as one (or more) of the following:
  • * Symptomatic HFpEF, defined by signs and symptoms of HF (dyspnea, fatigue), normal left ventricular (LV) EF (≥50% within 12 months of enrollment), and objective evidence of HF fulfilling at least one of the following criteria: Prior hospitalization for decompensated HF treated with intravenous diuretics; Invasively verified HFpEF defined by pulmonary capillary wedge pressure (PCWP) of ≥15 mmHg at rest and/or ≥25 mmHg during exercise; Clinical diagnosis of HFpEF that does not meet criteria i. or ii. but verified with NTproBNP\>300 pg/ml in sinus rhythm or \>900 pg/ml in AF; H2FPEF score ≥6 or HFA-PEFF score≥5 according to current guidelines.
  • * Symptomatic HFrEF, defined by defined by signs and symptoms of HF (dyspnea, fatigue) and reduced EF (\<50%).
  • * Symptomatic valvular heart disease (VHD), defined by signs and symptoms of HF (dyspnea, fatigue) in tandem with clinically significant aortic or mitral valve disease (regurgitation and/or stenosis).
  • * Patient inability or unwillingness to undergo noninvasive echocardiography, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case.
  • * WSPH Group 1 Pulmonary hypertension or PH (Pulmonary arterial hypertension; including congenital heart disease)
  • * Group 3 PH (Hypoxia/Lung disease-related PH)
  • * Group 4 PH (Thromboembolic PH)
  • * Group 5 PH (Miscellaneous)
  • * Clinically significant parenchymal lung disease, hypoxemia, or lung infection
  • * Amyloid/infiltrative cardiomyopathy
  • * Acute Myocarditis
  • * Acute coronary syndrome or revascularization within 90 days
  • * Use of PH-specific drugs
  • * Constrictive pericarditis
  • * High output heart failure
  • * HF hospitalization within the preceding 30 days
  • * Severe or greater aortic (AVA \< 1.0 cm2, Mean Gradient \> 40 mmHg) or severe mitral (MVA \< 1.0 cm) stenosis
  • * Inability or unwillingness to exercise
  • * Inadequate echocardiographic imaging windows
  • * Inability or unwillingness to cooperate with breath holding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Barry Borlaug, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2028-05